News - Empatic
2009-11-23 07:00:00
SAN DIEGO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that four senior executives have joined the organization, strengthening the management team that is driving the development of its obesity franchise.
OREXIGEN(TM) Therapeutics Reports 48-Week Results of Phase IIb Trial of Empatic(TM) to Treat Obesity
2008-01-07 09:00:10
Orexigen™ Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders, including obesity, today announced the 48-week results of the Phase IIb clinical trial of Empatic™, one of its two obesity drug candidates.